Key Drivers
- High cash buffer
- Sustained losses
- Financing dependent
AIAI Summary
Tango has shifted from a burn-stage biotech into a near-term, catalyst-driven precision oncology bet where valuation is now largely binary and contingent on upcoming PRMT5 (vopimetostat) readouts and partnership milestones rather than steady cash flows; investors should therefore treat TNGX as a high-upside, event-timed speculative trade and directly monitor the next clinical data releases, milestone payments/partner deals, and quarterly burn rate as primary triggers for re-rating or dilution. If PRMT5 data replicate and trigger expanded partnerships or non-dilutive milestones, upside is meaningful; conversely, negative/ delayed results or the need for large equity raises would likely cause a sharp repricing.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash buffer
- •Sustained losses
- •Financing dependent
TNGX has a very strong liquidity position and low leverage but is saddled with large operating losses, negative free cash flow, heavy R&D spending that outstrips revenue, and dependence on external financing despite a rich market valuation.
Price Behavior
Key Price Behavior Insights:
- •Sustained uptrend
- •Breakout confirmed
- •High intraday volatility
Over the last month TNGX displayed strong bullish momentum—rising from $12.20 to $19.42 with a clear breakout above the $16.5–$17.9 congestion zone but heightened short-term volatility (notably a gap from $12.35 to $16.83) that raises retracement risk, so prefer a pullback to confirmed support or a volume-backed continuation before adding exposure.
Major gap from $12.35 to $16.83 indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Institutional inflows
- •Erasca collaboration
- •Upcoming catalysts
Tango Therapeutics drew sizable institutional buying and a record-high rally after an Erasca collaboration, supported by constructive analyst coverage and upcoming 2026 catalysts despite an insider sale.
Positive institutional interest and partnership news should sustain upside momentum into near-term clinical readouts, barring negative trial results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings